E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,
Farhad Ravandi,Stefan Faderl,Jorge E. Cortes,Guillermo Garcia-Manero,Elias Jabbour,Patricia Ann Boone,Tapan M. Kadia,Gautam Borthakur,William G. Wierda,Meir Wetzler,Parameswaran Venugopal,Judy Chiao,Hagop M. Kantarjian +12 more
TL;DR: The sequential combination of decitabine and sapacItabine is safe and active in elderly AML, and the primary efficacy endpoint is response rate (CR, CRp, PR, or major HI).
Journal ArticleDOI
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Guillermo Montalban-Bravo,Danielle Hammond,Courtney D. DiNardo,Marina Konopleva,Gautam Borthakur,Nicholas J. Short,Jorge Ramos-Perez,Veronica A Guerra,Rashmi Kanagal-Shamanna,Kiran Naqvi,Koji Sasaki,Elias Jabbour,Naveen Pemmaraju,Tapan M. Kadia,Farhad Ravandi,Naval Daver,Zeev Estrov,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +19 more
Journal ArticleDOI
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
Tapan M. Kadia,Guillermo Garcia-Manero,Musa Yilmaz,Courtney D. DiNardo,Marina Konopleva,Guillermo Montalban-Bravo,Gautam Borthakur,Elias Jabbour,Nitin Jain,Michael Andreeff,Nicholas J. Short,Ghayas C. Issa,Maro Ohanian,Prithviraj Bose,Naval Daver,Sa A. Wang,Rebecca S. S. Tidwell,Zeev Estrov,Farhad Ravandi,Hagop M. Kantarjian +19 more
TL;DR: Ven is a BCL2 inhibitor that is approved in combination with lower intensity therapy for pts with newly diagnosed AML who are ineligible for intensive chemo, and it is shown that this combination is effective in reducing the need for intensive chemotherapy.
Journal ArticleDOI
The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia
Maro Ohanian,Hagop M. Kantarjian,Mahran Shoukier,Sara Dellasala,Arine Musaelyan,Graciela M. Nogueras González,Elias Jabbour,Lynne V. Abruzzo,Srdan Verstovsek,Gautam Borthakur,Farhad Ravandi,Guillermo Garcia-Manero,Gevorg Tamamyan,Richard E. Champlin,Sherry Pierce,Alessandra Ferrajoli,Tapan M. Kadia,Jorge E. Cortes +17 more
TL;DR: In de novo CML‐AP, early response at 3 and 6 months is a strong determinant of long‐term outcome, and the impact of various degrees of molecular and cytogenetic response at early time points is determined.
Journal ArticleDOI
A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Naval Daver,Rita Assi,Farhad Ravandi,Guillermo Garcia-Manero,Elias Jabbour,Courtney D. DiNardo,Tapan M. Kadia,Jing Ning,Graciela M. Nogueras-Gonzalez,Sherry Pierce,Dan S. Gombos,Steven M. Kornblau,Marina Konopleva,Mary A. Kelly,Gautam Borthakur,Weiguo Zhang,Jorge E. Cortes,Hagop M. Kantarjian,Michael Andreeff +18 more
TL;DR: AML-025 A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients with Relapsed and/or Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)